Continuous glucose monitoring improved glycaemic control in pregnant women with diabetes and reduced infant macrosomia
H R Murphy
Dr H R Murphy, University of Cambridge, Cambridge, UK; email@example.com
Does continuous glucose monitoring (CGM) improve glycaemic control in pregnant women with diabetes and reduce infant macrosomia?
randomised controlled trial. Current Controlled Trials ISRCTN84461581.
2 diabetes antenatal clinics in the UK.
71 pregnant women (mean age 31 y, mean gestational age 9 wks) who had type 1 diabetes (65% of women) or type 2 diabetes (35%) treated with insulin.
CGM plus standard antenatal care (n = 38) or standard care alone (n = 33). CGM was done every 4–6 weeks until 32 weeks of gestation. A subcutaneous sensor, attached to a portable monitor, was implanted by a nurse into the woman’s hip and worn for 5–7 days. The device recorded average tissue glucose concentrations every 5 minutes, but results were …